Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB
Ratings Surperformance© - Laboratorios Farmaceuticos Rovi, S.A.

Ratings ESG MSCI

Ratings ESG MSCI - Laboratorios Farmaceuticos Rovi, S.A.

Ratings Laboratorios Farmaceuticos Rovi, S.A.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Highlights: Laboratorios Farmaceuticos Rovi, S.A.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
  • Historically, the company has been releasing figures that are above expectations.
Weaknesses: Laboratorios Farmaceuticos Rovi, S.A.
  • With an enterprise value anticipated at 3.82 times the sales for the current fiscal year, the company turns out to be overvalued.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Rating Financials

Laboratorios Farmaceuticos Rovi, S.A. SectorSpain

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings
Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.

Rating Valuation

Laboratorios Farmaceuticos Rovi, S.A. SectorSpain

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings
Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.

Rating Consensus

Laboratorios Farmaceuticos Rovi, S.A. SectorSpain

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings
Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.

Rating Business Predictability

Laboratorios Farmaceuticos Rovi, S.A. SectorSpain

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.

Rating Revisions

Laboratorios Farmaceuticos Rovi, S.A. SectorSpain

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings
Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
332.42Cr
BBB
1,05100Cr
A
63TCr
BBB
49TCr
AAA
-
36TCr
AA
34TCr
AA
27TCr
AAA
25TCr
A
22TCr
BBB
19TCr
AA
Average 38.07TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. ROVI Stock
  4. Ratings Laboratorios Farmaceuticos Rovi, S.A.